1. Scrip

First US Branded Ophthalmic Launch A ‘Milestone’ For Sun

 
• By Penelope MacRae

India’s biggest drug firm Sun has just launched its first branded ophthalmic product in the US, marking what the company calls “a milestone” in its quest to build scale and seek steady revenue streams in the global specialty drug business.

A year ago, Sun Pharmaceutical Industries Ltd. paid $48m for California-based InSite Vision Inc., which focuses on developing specialty ophthalmic products. The purchase was a key building block in the strategy of Sun Pharma’s US subsidiary to transition to a specialty company that will in-license and develop branded products for the crucial US market.

Sun head Dilip Shanghvi, a low-profile tycoon who is India’s second-richest person with an estimated worth of $14.9bn, says the company’s evolving specialty portfolio will help “drive the sustainable growth of our business

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from New Products

More from Scrip

Stock Watch: Stock Watch: Lilly And Novo Duke Out Q1

 
• By Andy Smith

Novo Nordisk enjoyed a surprise GLP-1 agonist contracting win in the first quarter of 2025. This provided a welcome boost to its stock after it had spent the previous quarter on the back foot against rival Lilly.

Azafaros Banks Over €130m To Advance Nizubaglustat Into Phase III

 
• By Kevin Grogan

The therapy has been developed for GM1 and GM2 gangliosidoses and Niemann-Pick disease type C.

Sustainability Key To ABL Bio’s Journey From ‘Good To Great’

 
• By Jung Won Shin

Helped by a recent major platform deal with GSK, South Korea's ABL Bio is aiming to build its R&D portfolio with an eye on being acquired in the future. CEO Sang Hoon Lee sat down with Scrip to explain the venture's journey so far and its ambitious roadmap.